Milestone highlights cutting-edge advancements in stroke care, aneurysm treatment, and minimally invasive neuro interventions
Johnson & Johnson MedTech is marking 25 years of leadership in neurovascular care by unveiling a suite of innovative technologies at the Society of NeuroInterventional Surgery (SNIS) 2025 Annual Meeting. The announcement underscores the company’s ongoing mission to revolutionize treatment for stroke, aneurysms, and other life-threatening brain conditions through minimally invasive, data-driven solutions.
Image Credit: Charlie King
Key Innovations Spotlighted at SNIS 2025
As part of the celebration, J&J showcased a range of next-generation devices and AI-driven capabilities developed by its subsidiary, CERENOVUS, a global leader in neurovascular technology:
1. Cereglide™ 71 Intermediate Catheter
Designed to improve navigation and access in complex vascular anatomy during stroke interventions, enhancing precision and speed in mechanical thrombectomy procedures.
2. EMBOLD™ Fibered Coil
An advanced embolization device for treating brain aneurysms and hemorrhages, offering controlled deployment and strong anchoring in delicate neurovascular spaces.
3. Stroke Data Solutions Platform
A new data-analytics tool powered by AI and real-world evidence to help clinicians optimize patient outcomes and make informed procedural decisions faster.
Leadership Perspective
Mark Dickinson, Worldwide President, CERENOVUS, stated:
“Over the last 25 years, we’ve committed to advancing neurovascular science. The innovations we’re bringing to SNIS 2025 reflect our deep focus on clinician collaboration, AI integration, and evidence-based care.”
He added that Johnson & Johnson MedTech’s neurovascular pipeline is guided by an EVIDENCE. EXPERIENCE. ADVOCACY. framework—aimed at tackling the world’s leading causes of disability and death.
Why This Matters
Stroke remains the second leading cause of death globally. With innovations like Cereglide and EMBOLD, Johnson & Johnson is helping physicians treat stroke faster, more effectively, and with fewer complications.
The company’s 25-year commitment to neurovascular research is also driving the future of robotics, AI in surgery, and personalized care in neurology.
Source: Johnson & Johnson – 25 Years of Neurovascular Care & Innovation at SNIS 2025
